Published in J Immunol on October 15, 1999
Molecular pathways in virus-induced cytokine production. Microbiol Mol Biol Rev (2001) 1.97
Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol (2003) 1.83
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection. J Virol (2005) 1.08
FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog (2008) 1.06
Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci U S A (2001) 1.06
The role of IL-15 deficiency in the pathogenesis of virus-induced asthma exacerbations. PLoS Pathog (2011) 1.05
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clin Infect Dis (2015) 0.99
IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol (2015) 0.94
Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mech Ageing Dev (2011) 0.93
Activation mechanisms of natural killer cells during influenza virus infection. PLoS One (2012) 0.92
Porcine reproductive and respiratory syndrome virus induces interleukin-15 through the NF-κB signaling pathway. J Virol (2012) 0.90
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection. Curr HIV/AIDS Rep (2016) 0.87
Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta. J Immunol (2004) 0.81
Nuclear factor κB2 p52 protein has a role in antiviral immunity through IκB kinase epsilon-dependent induction of Sp1 protein and interleukin 15. J Biol Chem (2013) 0.80
Host's innate immune response to fungal and bacterial agents in vitro: up-regulation of interleukin-15 gene expression resulting in enhanced natural killer cell activity. Immunology (2003) 0.79
Experimental intestinal reovirus infection of mice: what we know, what we need to know. Immunol Res (2005) 0.79
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin Exp Immunol (2015) 0.78
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One (2013) 0.78
CD1d Expression and Invariant NKT Cell Responses in Herpesvirus Infections. Front Immunol (2015) 0.76
Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Curr Pharm Des (2007) 0.76
Killer immunoglobulin-like receptor expression on single cells: a cautionary note. Immunology (2003) 0.75
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation. Infect Immun (1976) 1.61
Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol (2001) 1.56
Genomic organization and mapping of transcription and translation products of the NADL-2 strain of porcine parvovirus. Virology (1993) 1.45
Presence of Epstein-Barr virus receptors, but absence of virus penetration, in cells of an Epstein-Barr virus genome-negative human lymphoblastoid T line (Molt 4). J Virol (1977) 1.44
Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV. Intervirology (1974) 1.42
A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection. Can Med Assoc J (1984) 1.35
Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients. J Virol Methods (1991) 1.33
Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood (1995) 1.28
Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol (1991) 1.11
Modulatory effects of Epstein-Barr, herpes simplex, and human herpes-6 viral infections and coinfections on cytokine synthesis. A comparative study. J Immunol (1992) 1.09
Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer (1999) 1.07
Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol (1993) 1.06
Use of fluoresceinated Epstein-Barr virus to study Epstein-Barr virus-lymphoid cell interactions. J Virol (1982) 1.06
Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr (1994) 1.04
Modulation of expression of the MHC class I-binding natural killer cell receptors, and NK activity in relation to viral load in HIV-infected/AIDS patients. J Med Virol (2001) 1.03
Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J (1996) 1.02
Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. J Virol (1996) 1.01
Persistence of CMV genome in lymphoid cells after congenital infection. Nature (1975) 1.01
Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-alpha. J Clin Invest (1992) 1.00
Inhibition of tumor necrosis factor-alpha transcription by Epstein-Barr virus. Eur J Immunol (1991) 1.00
Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases. J Mol Biol (2000) 0.99
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene (2006) 0.99
Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J Clin Invest (1996) 0.99
Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets. J Infect Dis (1994) 0.98
Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol (2000) 0.95
Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways. J Mol Biol (2001) 0.95
Differential interleukin-2 and interferon-gamma production by human lymphocyte cultures exceptionally resistant to Epstein-Barr virus immortalization. Cell Immunol (1989) 0.94
Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol (1997) 0.93
Antibody and antibody-dependent cellular cytotoxicity responses against the BamHI A rightward open-reading frame-1 protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J Infect Dis (1997) 0.93
Effect of interferon on lymphocyte transformation and nuclear antigen production by Epstein-Barr virus. Nature (1976) 0.93
Induction of Epstein-Barr virus-associated nuclear antigen during in vitro transformation of human lymphoid cells. J Natl Cancer Inst (1975) 0.93
The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int J Cancer (1998) 0.90
Differential effect of phosphonoacetic acid on early antigen synthesis in two Epstein-Barr virus producer cell lines. Virology (1979) 0.89
Chloroquine enhances Epstein-Barr virus expression. Nature (1978) 0.89
Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM. J Virol (2000) 0.89
Impaired induction of IL-15 in response to herpes simplex virus type 1 infection in peripheral blood mononuclear cells of HIV-infected patients. AIDS (2000) 0.89
Activated human platelets express Fas-L and induce apoptosis in Fas-positive tumor cells. J Leukoc Biol (2001) 0.87
Comparative studies on the induction of virus-associated nuclear antigen and early antigen by lymphocyte-transforming (B95-8) and nontransforming (P3HR-1) strains of Epstein-Barr virus. Intervirology (1978) 0.86
Epstein-Barr virus (EBV)--lymphoid cell interactions. II. The influence of the EBV replication cycle on natural killing and antibody-dependent cellular cytotoxicity against EBV-infected cells. Clin Exp Immunol (1982) 0.85
Positive correlation between the natural killer and gp 120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.85
Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes. J Gen Virol (1990) 0.84
Comparative studies on the expression of Fc-receptors, Ia antigens, and beta 2-microglobulin following in vitro herpes simplex virus infection of human lymphoid cells. Clin Exp Immunol (1979) 0.84
Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J Natl Cancer Inst (2001) 0.84
Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies. Virology (1993) 0.84
Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.82
Junctions and spiral patterns in generalized rock-paper-scissors models. Phys Rev E Stat Nonlin Soft Matter Phys (2012) 0.82
Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta. J Immunol (1997) 0.82
Virus load correlates inversely with the expression of cytotoxic T lymphocyte activation markers in HIV-1-infected/AIDS patients showing MHC-unrestricted CTL-mediated lysis. Clin Exp Immunol (2003) 0.81
The effect of indomethacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells. Antiviral Res (1990) 0.81
Thrombin induces apoptosis in human tumor cells. Int J Cancer (2000) 0.81
Epstein-Barr virus (EBV) expression in transformed human lymphoblastoid cell lines from different sources. Bibl Haematol (1975) 0.81
Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines. Infect Immun (1982) 0.81
von Neummann's and related scaling laws in rock-paper-scissors-type games. Phys Rev E Stat Nonlin Soft Matter Phys (2012) 0.81
Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease. Blood (1994) 0.80
Detection of immunosuppressive early pregnancy factor in humans. Indian J Med Res (1987) 0.80
Herpesvirus-lymphoid cell interactions: comparative studies on the biology of herpes simplex virus-induced Fc receptors in B, T, and "null" lymphoid cell lines. J Virol (1980) 0.80
Epstein-Barr virus-lymphoid cell interactions. III. Effect of concanavalin A and saccharides on Epstein-Barr virus penetration. J Virol (1982) 0.80
Characterization of human gamete centrosomes for assisted reproduction. Ital J Anat Embryol (2001) 0.79
Surface expression of the HIV-1 envelope proteins in env gene-transfected CD4-positive human T cell clones: characterization and killing by an antibody-dependent cellular cytotoxic mechanism. J Acquir Immune Defic Syndr (1994) 0.79
Isoprinosine enhances the activation of sensitized lymphocytes by Epstein-Barr virus antigens. Int J Immunopharmacol (1985) 0.79
Epstein-Barr virus envelope glycoprotein gp350 induces NF-kappaB activation and IL-1beta synthesis in human monocytes-macrophages involving PKC and PI3-K. FASEB J (1999) 0.79
Nasopharyngeal carcinoma and Burkitt's lymphoma in a Canadian family. I. HLA typing, EBV antibodies and serum immunoglobulins. Can Med Assoc J (1976) 0.79
Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear cell function in Crohn's disease and ulcerative colitis. J Pediatr Gastroenterol Nutr (1993) 0.78
Staphylococcal protein A enhances natural killing activity against lymphoid tumor cell lines. Int J Cancer (1981) 0.78
Sendai virus envelopes can mediate Epstein-Barr virus binding to and penetration into Epstein-Barr virus receptor-negative cells. J Virol (1983) 0.78
Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen-induced lymphocyte response. Int J Cancer (1982) 0.78
Involvement of macrophage-like cells in growth of tumors induced by avian sarcoma virus. Cancer Res (1983) 0.78
Comparative study of herpes simplex virus receptor expression on human lymphoid cells. Virology (1990) 0.78
Human gamma interferon induction by staphylococcal protein A: effector cells, kinetics and the effect of prostaglandin, indomethacin, ibuprofen and aspirin. Int J Immunopharmacol (1988) 0.78
Studies on the induction of IgG-Fc receptors and synthesis of IgM in primary and chronically-infected lymphoid (Raji) cells by herpes simplex virus. J Gen Virol (1979) 0.77
Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells. Viral Immunol (1990) 0.77
A new class of infectious agents detectable by the production of chorioallantoic membrane lesions by human lymphoblastoid cell lines and their culture supernatants. J Natl Cancer Inst (1977) 0.77
Retinoic acid and steroids inhibit Epstein-Barr virus-induced nuclear antigen, DNA synthesis and lymphocyte transformation. Anticancer Res (1985) 0.77
Effect of monoclonal antibodies to Epstein-Barr virus envelope glycoproteins on Epstein-Barr virus neutralization and binding to target cell receptors. A comparative analysis. Intervirology (1990) 0.77
CD8+ suppressor cells inhibit staphylococcal protein A-induced gamma interferon production by CD4+ lymphocytes. Immunol Lett (1991) 0.77
Modulatory effects of human herpes virus-7 on cytokine synthesis and cell proliferation in human peripheral blood mononuclear cell cultures. J Leukoc Biol (1999) 0.76
The relationship between concentrations of prostaglandin A1, E1, E2 and E2alpha and rates of cell proliferation. Pharmacol Res Commun (1979) 0.76
Rosette formation by human lymphoid cells with monkey red blood cells. Ann Immunol (Paris) (1978) 0.76
Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity. Clin Exp Immunol (1984) 0.75
Effect of adoptive transfer of CD4, CD8 and B cells on recovery from MHV3-induced immunodeficiencies. Immunology (1996) 0.75
The fluorescent staining of a mycobacteriophage (C2) nucleic acid. Can J Microbiol (1971) 0.75
Clinical relevance of serum immunoglobulin A antibodies to Epstein-Barr virus envelope glycoprotein gp350 in nasopharyngeal carcinoma patients. J Clin Microbiol (1998) 0.75
[In vitro cytokine induction in leukocytes by human herpesvirus 7]. Orv Hetil (1999) 0.75
Properties of mycobacteriophage C2. Experientia (1969) 0.75
[Presence of antibodies to human herpesvirus type 6 and 7 in Hungarian children]. Orv Hetil (1999) 0.75
Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones. Int J Cancer (1991) 0.75
Role of Vicia villosa-adherent CD8+ T cells in the immune response to Epstein-Barr virus. Viral Immunol (1991) 0.75
Epstein-Barr virus immunosuppression: II. Generation of nonspecific suppressor T lymphocytes in vitro. Microb Pathog (1987) 0.75
Differences in Epstein-Barr virus (EBV) receptors expression on various human lymphoid targets and their significance to EBV-cell interaction. Virus Res (1988) 0.75
Infection of a murine T-cell line with a retrovirus carrying c-myc decreases the interleukin-2 cell dependence by a nonautocrine mechanism. J Leukoc Biol (1988) 0.75
Tac expression induced by Epstein-Barr virus is restricted on non-transformable B lymphocytes. Immunol Lett (1988) 0.75
IgG from Epstein-Barr virus infectious mononucleosis patients inhibits interleukin-2 production. Int J Immunopharmacol (1987) 0.75
Differential staphylococcal protein A-induced enhancement of natural killer cell activity of lymphocytes from HIV-seropositive individuals. Int J Immunopharmacol (1991) 0.75